ArticleImmunologic research2026
Regional variation in serum ficolin levels and their association with disease activity and clinical manifestations in systemic lupus erythematosus (SLE) patients from India.
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Funding
Abstract
The lectin pathway, activated by ficolins, contributes to systemic lupus erythematosus (SLE) pathogenesis, but ficolin data remain inconsistent across populations. Present muti-centric cross-sectional study assessed serum ficolin-1, -2, and - 3 levels and their associations with clinical features and disease activity among SLE patients from five Indian regions (Mumbai, Assam, Meghalaya, Manipur, and Nagaland). Serum levels of ficolin-1, ficolin-2, and ficolin-3 were measured using ELISA. Disease activity was assessed using the SELENA-SLEDAI score. Statistical analyses were performed using non-parametric tests, with p < 0.05 considered significant. Serum ficolin levels differed significantly by region. Ficolin-1 and ficolin-2 levels were positively correlated with the renal involvement in SLE patients from Mumbai (r = 0.218; p < 0.001 and r = 0.199; p = 0.001, respectively), while ficolin-1 levels were also correlated with lupus nephritis (LN) in SLE patients from Manipur (r = 0.247; p = 0.040). In Assam, ficolin-2 levels were significantly reduced in patients with mucocutaneous manifestations (r=-0.258; p = 0.014), and ficolin-3 levels showed a negative correlation with musculoskeletal manifestations (r=-0.217; p = 0.040). In Mumbai, ficolin-1 levels were positively associated with disease activity (r = 0.139; p = 0.018), and ficolin-3 levels correlated positively with anti-dsDNA autoantibodies (r = 0.172; p = 0.004). Conversely, ficolin-3 levels showed a negative correlation with anti-dsDNA (r=-0.470; p < 0.001) in Assam. The present study demonstrated significant regional variations in ficolin levels among SLE patients across India. Association of ficolin-1 and ficolin-3 with specific organ involvement suggested their potential as possible immunological indicators in SLE. These findings suggested the importance of considering regional and ethnic differences in SLE management and warranted further validation through larger, longitudinal studies.
Indexed as
Identifiers
41483420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.